Reimbursement is expected in the second half of 2026 in the most optimistic scenario
Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology
Front Synaptic Neurosci 10:13 Dey SK, Saini M, Prabhakar P, Kundu S (2020) Dopamine hydroxylase as a potential drug target to combat hypertension
You should always consult with your physician before stopping or changing medications or taking on new health strategies
HCG Injections B12 Shots Lipotropic Injections Glutathione Injections Ozempic Injections Mounjaro Injections Wegovy Injections Saxenda Injections Testosterone Therapy Supervised Weight Loss Products Discover safe and effective Weight Loss Products.
Chenna S, Koopman WJH, Prehn JHM, Connolly NMC
